0
Skip to Content
BLOODPAC
BLOODPAC
About
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Approach
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Data
BLOODPAC Portal
BLOODPAC Data Commons
Impact
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Resources
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
BLOODPAC
BLOODPAC
About
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Approach
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Data
BLOODPAC Portal
BLOODPAC Data Commons
Impact
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Resources
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
Folder: About
Back
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Folder: Approach
Back
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Folder: Data
Back
BLOODPAC Portal
BLOODPAC Data Commons
Folder: Impact
Back
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Folder: Resources
Back
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
Understanding Liquid Biopsy for Brain Cancer
Liquid Biopsy Technology Guest User 4/20/23 Liquid Biopsy Technology Guest User 4/20/23

Understanding Liquid Biopsy for Brain Cancer

Any cancer diagnosis is devastating, but the discovery of a brain tumor comes with a unique set of challenges for both patient and doctor. In this article, we discuss the potential role of liquid biopsy for management of brain cancer, current research in this space, and remaining questions in the field.

Read More
BLOODPAC Hosts Brain Cancer Virtual Webinar
News Laura Tramontozzi 7/14/22 News Laura Tramontozzi 7/14/22

BLOODPAC Hosts Brain Cancer Virtual Webinar

Read More

ABOUT

BLOODPAC is a consortium managed by the Center for Computational Science Research, Inc. (CCSR), which is an Illinois based 501 (c)(3) not-for-profit corporation. Our mission is to accelerate the development, validation, and accessibility of liquid biopsy assays to improve outcomes for patients with cancer. To do so, we lead a pre-competitive collaborative infrastructure that enables the sharing of information and building of consensus among stakeholders in industry, academia, regulatory bodies, payers, and government agencies.